Leica Biosystems

Leica Biosystems (a proud subsidiary of Danaher Corporation) is a global leader in anatomic pathology and cancer workflow solutions, operating with a mission of "Advancing Cancer Diagnostics, Improving Lives." It is unique in the industry as one of the few companies that owns and optimizes the entire clinical pathway—spanning from initial tissue biopsy and sample preparation to advanced staining, digital imaging, and reporting. By breaking down technical barriers between individual laboratory steps, the platform helps clinical and research networks streamline operations, increase throughput, and deliver confident, precise answers to over 1.6 million patient diagnoses each week.

The Aperio Digital Pathology portfolio serves as a comprehensive, modular framework designed to transition physical laboratories into high-efficiency digital workspaces. The ecosystem is categorized into three critical areas:

Scan: High-resolution digital imaging systems, featuring the state-of-the-art Aperio GT Elite high-throughput scanner. Equipped with embedded SmartScan™ technology, it uses barcode-driven automation to scan up to 103 slides per hour without manual sorting.

Manage: Scalable, secure data infrastructure (such as Aperio HALO AP) that allows pathology teams to easily organize, view, and remotely share complex Whole Slide Images (WSIs) across multi-site healthcare networks.

Analyze: Advanced computational tools, digital algorithms, and targeted analytical validation frameworks designed to assist with quantitative tissue analysis and biomarker research.

The Aperio AI Store is a curated, deeply integrated clinical and research hub available natively within the Aperio HALO AP software platform. Rather than locking laboratories into a closed system, Leica Biosystems uses an open, secure digital architecture that embeds advanced artificial intelligence tools from multiple leading global developers (such as Indica Labs, Lunit, Histofy, Deep Bio, Mindpeak, and DiaDeep). This centralized portal allows pathologists to access specialized, domain-specific AI models for tissue segmentation, H&E staining interpretation, and precise oncology biomarker quantification directly within their active digital workspace, minimizing software hopping and reducing case turnaround times.

To eliminate expensive slide rescans and manual inspection bottlenecks, Leica Biosystems integrates real-time, AI-driven quality control directly into its scanning hardware via the Aperio iQC software suite. When paired with high-throughput hardware like the Aperio GT Elite, the system leverages deep learning algorithms to automatically scan whole slide images for common artifacts—such as air bubbles, dust particles, tissue folding, or out-of-focus fields—while the slide is physically inside the machine. If a defect is flagged, the AI instantly alerts laboratory technicians, allowing them to fix the slide before it moves downstream into the diagnostic or research queue.